Can a framework be established for the safe use of ketamine?

American Journal of Psychiatry

Volumn 175, Issue 7, 2018, Pages 587-589

  Freedman, Robert ^a   Brown, Alan S ^a   Cannon, Tyrone D ^a   Druss, Benjamin G ^a   Earls, Felton J ^a   Escobar, Javier ^a   Hurd, Yasmin L ^a   Lewis, David A ^a   López Jaramillo, Carlos ^a   Luby, Joan ^a   Mayberg, Helen S ^a   Moffitt, Terrie E ^a   Oquendo, Maria ^a   Perlis, Roy H ^a   Pine, Daniel S ^a   Rush, A John ^a   Tamminga, Carol A ^a   Tohen, Mauricio ^a   Vieta, Eduard ^a   Wisner, Katherine L ^a   Xin, Yu ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

CONSENSUS DEVELOPMENT; DEPRESSION; DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MARKETING; DRUG MISUSE; DRUG MONITORING; DRUG SAFETY; DRUG URINE LEVEL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SUICIDE; TREATMENT RESPONSE; DOUBLE BLIND PROCEDURE;

DEPRESSION; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; HUMANS; KETAMINE; SUBSTANCE-RELATED DISORDERS; SUICIDE;

EID: 85049408362     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2018.18030290     Document Type: Editorial

References (8)

1. Canuso CM, Singh JB, Fedgchin M, et al: Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018; 175:620-630
2. Grunebaum MF, Galfalvy HC, Choo TH, et al: Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolamcontrolled randomized clinical trial. Am J Psychiatry 2018; 175: 327-335
3. National Drug Intelligence Center: West Virginia drug threat assessment: diverted pharmaceuticals. Aug 2003. https://www.justice.gov/archive/ndic/pubs5/5266/index.htm
4. Schak KM, Vande Voort JL, Johnson EK, et al: Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry 2016; 173:215-218
5. Sanacora G, Frye MA, McDonald W, et al: A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017; 74:399-405
6. Rocha BA, Ward AS, Egilmez Y, et al: Tolerance to the discriminative stimulus and reinforcing effects of ketamine. Behav Pharmacol 1996; 7: 160-168
7. Aaronson ST, Sears P, Ruvuna F, et al: A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry 2017; 174:640-648
8. Nazarian DJ, Broder JS, Thiessen MEW, et al: Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med 2017; 69:480-498